JOP20200227A1 - تركيبة صيدلانية جديدة تشتمل على مضادات مستقبلة ثنائية من نيوروكينين-1/نيوروكينين-3 - Google Patents
تركيبة صيدلانية جديدة تشتمل على مضادات مستقبلة ثنائية من نيوروكينين-1/نيوروكينين-3Info
- Publication number
- JOP20200227A1 JOP20200227A1 JOP/2020/0227A JOP20200227A JOP20200227A1 JO P20200227 A1 JOP20200227 A1 JO P20200227A1 JO P20200227 A JOP20200227 A JO P20200227A JO P20200227 A1 JOP20200227 A1 JO P20200227A1
- Authority
- JO
- Jordan
- Prior art keywords
- novel pharmaceutical
- dual
- pharmaceutical formulation
- receptor antagonists
- hexahydropyrazino
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 title 1
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 238000013160 medical therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- DWRIJNIPBUFCQS-DQEYMECFSA-N n-[6-[(7s,9as)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CN3CCOC[C@@H]3C2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DWRIJNIPBUFCQS-DQEYMECFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتعلق الاختراع الحالي عموماً بتركيبات صيدلانية تحتوي على 2-[3، 5-ثنائي (ثلاثي فلورو مثيل) فنيل]-N-{4-(4-فلورو-2-مثيل فنيل) -6-[(7S، 9aS)-7-(هيدروكسي ميثيل) سداسي هيدروبيرازينو [2، 1-جـ] [1، 4] أوكسازين-8 (1H)-يل]-3-بيريدينيل}-N، 2-ثنائي مثيل بروباناميد وطرق تحضيرها واستخدامها في العلاج الطبي. الشكل 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642622P | 2018-03-14 | 2018-03-14 | |
| PCT/EP2019/056303 WO2019175253A1 (en) | 2018-03-14 | 2019-03-13 | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200227A1 true JOP20200227A1 (ar) | 2020-09-13 |
Family
ID=65817992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0227A JOP20200227A1 (ar) | 2018-03-14 | 2019-03-13 | تركيبة صيدلانية جديدة تشتمل على مضادات مستقبلة ثنائية من نيوروكينين-1/نيوروكينين-3 |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US10774091B2 (ar) |
| EP (1) | EP3765024B1 (ar) |
| JP (1) | JP7433252B2 (ar) |
| KR (1) | KR20200139138A (ar) |
| CN (1) | CN112292132A (ar) |
| AU (1) | AU2019233606A1 (ar) |
| BR (1) | BR112020017388A2 (ar) |
| CA (1) | CA3092238A1 (ar) |
| CL (1) | CL2020002350A1 (ar) |
| CO (1) | CO2020011262A2 (ar) |
| CR (1) | CR20200385A (ar) |
| DK (1) | DK3765024T3 (ar) |
| EA (1) | EA202092131A1 (ar) |
| EC (1) | ECSP20057488A (ar) |
| ES (1) | ES2974300T3 (ar) |
| FI (1) | FI3765024T3 (ar) |
| GE (1) | GEP20237503B (ar) |
| HR (1) | HRP20240120T1 (ar) |
| HU (1) | HUE065300T2 (ar) |
| IL (1) | IL276959B1 (ar) |
| JO (1) | JOP20200227A1 (ar) |
| LT (1) | LT3765024T (ar) |
| MA (1) | MA51999B1 (ar) |
| MX (2) | MX2020009438A (ar) |
| PE (1) | PE20210395A1 (ar) |
| PH (1) | PH12020551457A1 (ar) |
| PT (1) | PT3765024T (ar) |
| RS (1) | RS65257B1 (ar) |
| SG (1) | SG11202008226YA (ar) |
| SI (1) | SI3765024T1 (ar) |
| WO (1) | WO2019175253A1 (ar) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10906874B2 (en) | 2016-09-18 | 2021-02-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | YAP1 inhibitors that target the interaction of YAP1 with OCT4 |
| PT3765024T (pt) | 2018-03-14 | 2024-02-19 | Kandy Therapeutics Ltd | Formulação farmacêutica inovadora que compreende antagonistas duplos dos recetores nk-1/nk-3 |
| AU2019236196A1 (en) | 2018-03-14 | 2020-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | YAP1 inhibitors that target the interaction of YAP1 with Oct4 |
| KR20220101090A (ko) | 2019-11-15 | 2022-07-19 | 칸디 테라퓨틱스 리미티드 | Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법 |
| KR102484687B1 (ko) * | 2022-03-04 | 2023-01-05 | (주)씨앤엘디 | 페노피브레이트를 포함하는 이상지질혈증의 예방 또는 치료용 약학 조성물 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3097618A (en) | 1960-12-01 | 1963-07-16 | Raymond Bag Corp | Manufacture of multi-wall bag having heat-sealed liner |
| DE4322826A1 (de) * | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
| GB9907571D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Compounds |
| EP1299100B1 (en) | 2000-06-12 | 2007-07-25 | The University Of Rochester | Method of treating hot flashes, using tachykinin receptor antagonist |
| EP1192952A3 (en) | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| WO2002089802A2 (en) | 2001-05-08 | 2002-11-14 | Schering Corporation | Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
| CA2509090C (en) | 2002-12-23 | 2012-01-24 | Janssen Pharmaceutica N.V. | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists |
| JO2696B1 (ar) | 2002-12-23 | 2013-03-03 | شركة جانسين فارماسوتيكا ان. في | مشتقات 1-بيبردين -4-يل-4-بيبروليدين -3-يل -بيبرازين مستبدلة واستخدامها كمضادات كينين |
| US7525659B2 (en) | 2003-01-15 | 2009-04-28 | Negevtech Ltd. | System for detection of water defects |
| EP1643998B1 (en) | 2003-07-03 | 2007-08-29 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
| JO2676B1 (ar) | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | مشتقات ثاني آزا-سبيرو-(5,4)-ديكان واستعمالها كمضادات لنيروكين |
| JO2525B1 (ar) | 2004-04-08 | 2010-03-17 | شركة جانسين فارماسوتيكا ان. في | مشتقات 4-الكيل-و4-الكانويل بيبيريدين مستبدلة واستعمالها كمضادات لنيروكين |
| CA2565953A1 (en) | 2004-05-12 | 2005-11-24 | Pfizer Products Inc. | Piperidine derivatives as nk1 and nk3 antagonists |
| DE102004033902A1 (de) | 2004-07-14 | 2006-02-16 | Zentaris Gmbh | Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's) |
| WO2006013205A1 (en) | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
| US20060030600A1 (en) | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| KR101292348B1 (ko) * | 2005-09-09 | 2013-09-09 | 네르 쎄라퓨틱스 리미티드 | 피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도 |
| AU2008240804B2 (en) | 2007-04-20 | 2013-02-21 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists |
| GB0814340D0 (en) | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| AU2010288502B2 (en) * | 2009-08-27 | 2013-12-12 | KaNDy Therapeutics Ltd. | Anhydrate forms of a pyridine derivative |
| US8487102B2 (en) | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| ES2376564B1 (es) | 2010-08-12 | 2013-01-24 | Manuel Vicente Salinas Martín | Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer. |
| GB2488788B (en) * | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| WO2013082388A1 (en) | 2011-12-02 | 2013-06-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Peptide deformylase inhibitors |
| KR101739820B1 (ko) | 2012-03-28 | 2017-05-25 | 주식회사유한양행 | 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물 |
| US20150272927A1 (en) | 2012-12-03 | 2015-10-01 | University Of Washington Through Its Center For Commercialization | Methods and compositions for treating vasomotor symptoms |
| GB201315846D0 (en) | 2013-09-05 | 2013-10-23 | Imp Innovations Ltd | Method for treating or preventing hot flushes |
| ES2753539T3 (es) * | 2015-05-18 | 2020-04-13 | Nerre Therapeutics Ltd | Antagonista del receptor NK-1/NK-3 para el tratamiento de los sofocos |
| PT3765024T (pt) | 2018-03-14 | 2024-02-19 | Kandy Therapeutics Ltd | Formulação farmacêutica inovadora que compreende antagonistas duplos dos recetores nk-1/nk-3 |
| KR20220101090A (ko) | 2019-11-15 | 2022-07-19 | 칸디 테라퓨틱스 리미티드 | Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법 |
-
2019
- 2019-03-13 PT PT197118664T patent/PT3765024T/pt unknown
- 2019-03-13 EA EA202092131A patent/EA202092131A1/ru unknown
- 2019-03-13 ES ES19711866T patent/ES2974300T3/es active Active
- 2019-03-13 PE PE2020001406A patent/PE20210395A1/es unknown
- 2019-03-13 HR HRP20240120TT patent/HRP20240120T1/hr unknown
- 2019-03-13 FI FIEP19711866.4T patent/FI3765024T3/fi active
- 2019-03-13 JP JP2020572615A patent/JP7433252B2/ja active Active
- 2019-03-13 CN CN201980019147.6A patent/CN112292132A/zh active Pending
- 2019-03-13 RS RS20240167A patent/RS65257B1/sr unknown
- 2019-03-13 BR BR112020017388-6A patent/BR112020017388A2/pt unknown
- 2019-03-13 EP EP19711866.4A patent/EP3765024B1/en active Active
- 2019-03-13 MX MX2020009438A patent/MX2020009438A/es unknown
- 2019-03-13 WO PCT/EP2019/056303 patent/WO2019175253A1/en active Application Filing
- 2019-03-13 SI SI201930698T patent/SI3765024T1/sl unknown
- 2019-03-13 KR KR1020207026436A patent/KR20200139138A/ko unknown
- 2019-03-13 JO JOP/2020/0227A patent/JOP20200227A1/ar unknown
- 2019-03-13 MA MA51999A patent/MA51999B1/fr unknown
- 2019-03-13 US US16/351,659 patent/US10774091B2/en active Active
- 2019-03-13 DK DK19711866.4T patent/DK3765024T3/da active
- 2019-03-13 SG SG11202008226YA patent/SG11202008226YA/en unknown
- 2019-03-13 HU HUE19711866A patent/HUE065300T2/hu unknown
- 2019-03-13 LT LTEPPCT/EP2019/056303T patent/LT3765024T/lt unknown
- 2019-03-13 CA CA3092238A patent/CA3092238A1/en active Pending
- 2019-03-13 GE GEAP201915464A patent/GEP20237503B/en unknown
- 2019-03-13 IL IL276959A patent/IL276959B1/en unknown
- 2019-03-13 CR CR20200385A patent/CR20200385A/es unknown
- 2019-03-13 AU AU2019233606A patent/AU2019233606A1/en active Pending
-
2020
- 2020-08-04 US US16/984,961 patent/US11591346B2/en active Active
- 2020-08-04 US US16/985,087 patent/US11787820B2/en active Active
- 2020-09-10 MX MX2022005706A patent/MX2022005706A/es unknown
- 2020-09-11 CO CONC2020/0011262A patent/CO2020011262A2/es unknown
- 2020-09-11 CL CL2020002350A patent/CL2020002350A1/es unknown
- 2020-09-11 PH PH12020551457A patent/PH12020551457A1/en unknown
- 2020-09-14 EC ECSENADI202057488A patent/ECSP20057488A/es unknown
-
2023
- 2023-01-13 US US18/097,046 patent/US11767328B2/en active Active
- 2023-07-31 US US18/228,593 patent/US20230382922A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551457A1 (en) | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists | |
| EP4249076A3 (en) | (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor | |
| ZA202000300B (en) | Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | |
| MY181439A (en) | Substituted quinoline compounds and methods of use | |
| WO2014022116A3 (en) | Substituted pyrazolone compounds and methods of use | |
| HRP20110457T1 (hr) | Derivati piridina i njihova upotreba u liječenju psihotičnih poremećaja | |
| MX2015009950A (es) | Compuestos de imidazopiridina y sus usos. | |
| PH12018501137A1 (en) | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one | |
| EP3452455A4 (en) | SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES | |
| EP3440080A4 (en) | PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| EP3440083A4 (en) | IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER | |
| EP3440081A4 (en) | PYRROLO [1,2-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| MX2023002553A (es) | Compuestos de quinolina antagonistas del cgas. | |
| WO2014193647A3 (en) | Alkenyl compounds and methods of use | |
| JO2550B1 (ar) | مشتقات بيريدو [3,2-d] بيريميدين, تحضيرها, استخدامها علاجيا | |
| IL283976A (en) | Methyl {6,4-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[4,3-b]pyridin-3-yl]pyrimidin-5-yl}carbamate Active compound product having Its improved properties, manufacture and formulation | |
| EP3131553A4 (en) | SOLID FORMS OF 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE | |
| MX2015014905A (es) | Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos. | |
| EP3997088A4 (en) | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | |
| PH12015502420A1 (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | |
| IL271628A (en) | A new salt of N-(6,2-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-5,4-dihydro-1H -pyrazolo[3,4-H]quinazoline-3-carboxamide, its preparation and formulations containing it | |
| MY188809A (en) | Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide | |
| EA201991473A1 (ru) | Имидазопирролопиридин в качестве ингибиторов киназ семейства jak | |
| TH1501006326A (th) | สูตรผสมทางเภสัชกรรม, กระบวนการ, รูปแบบของแข็ง และวิธีของการใช้ที่เกี่ยวข้องกับ 1-เอธิล-7-(2-เมธิล-6-(1h-1,2,4-ไทรอะโซล-3-อิล) ไพริดิน-3-อิล)-3,4-ไดไฮโดรไพราซิโน[2,3-b]ไพราซิน-2(1h)-โอน | |
| NZ629866A (en) | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof |